Αρχική World News FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients... World News FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Από Ogkologos - 11 Φεβρουαρίου, 2026 346 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... 16 Αυγούστου, 2021 FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... 8 Μαρτίου, 2024 Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer 24 Ιουνίου, 2020 Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity... 16 Ιανουαρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma Pharmacokinetically Guided Dose Optimisation of Oral Targeted Therapies Reduces the Proportion... FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated... Holiday Lights Are My Favorite Thing